The U.S. FDA approved Idarucizumab for neurological disorders on October 16, 2015. Idarucizumab is an antidote it is a special medicine that can reverse the effects of another medication called dabigatran. 

Idarucizumab treats adults to rapidly reverse its effects in emergencies, including surgeries and life-threatening bleeding. Anticoagulant therapies are initiated to prevent and treat blood clot formation in conditions like thromboembolism.

Idarucizumab will be administered to you by a healthcare professional in a hospital setting. It is usually administered in the vein. Your doctor will decide the dose, route of administration, and frequency based on your disease condition and other factors.

Side effects are unwanted symptoms caused by medicines. Even though all medicines cause side effects, not everyone gets them. Idarucizumab is generally safe to consume and is not associated with significant side effects. However, consult your dietician for advice if you experience any unfamiliar side effects.

Do not take Idarucizumab if you are allergic to Idarucizumab or any of its ingredients.  Before starting the treatment, inform your physician if you have hereditary fructose intolerance. Your doctor will consider this information before administering the medicine. 

There is currently no available information regarding the use of this medicine in children. Each dose of this medicine contains 50 mg of sodium, so before you start the treatment, if you are on the sodium control diet. Notify your doctor if you are pregnant, planning to get pregnant, or think you may be pregnant or breastfeeding.

Note that this medicine eliminates Dabigatran from your system but does not affect other clot-preventing medications. After Dabigatran removal, you will still need blood clot prevention treatment based on your health condition. Follow the prescribed dosage and administration instructions provided by your healthcare professional. Inform your doctor about any known allergies or medical conditions you have before receiving Idarucizumab. If you notice any unexpected or severe side effects, such as difficulty breathing or an allergic reaction, seek immediate medical attention. Inform your healthcare professional about any other medications or supplements you are consuming to avoid potential drug interactions. If you have any concerns regarding the treatment, consult your healthcare professional for information.

1. Boehringer Ingelheim International GmbH, Electronic medicines compendium (emc), [Revised on Feb 2023] [Accessed 22nd August 2023], pil.5073.pdf (medicines.org.uk)
2. Boehringer Ingelheim Pharmaceuticals, Inc., US Food and Drug Administration, [ Revised on Oct 2015] [ Accessed on 22nd August 2023], PRAXBIND (idarucizumab) injection, for intravenous use (fda.gov)
3. James L. Zehnder, Drugs Used in Disorders of Coagulation, Lange’s Basic and Clinical Pharmacology, 14th Edition, 2018, 608-625.

The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you are eligible to receive this treatment.